Every material Form 8-K Prime Medicine, Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Prime Medicine reported second-quarter 2026 results, with its net loss narrowing to $42.1 million from $52.6 million a year earlier. Lower research and development and general and administrative spending drove the improvement, and the company also reported regulatory and arbitration updates for its pipeline. Cash, cash equivalents, investments and restricted cash fell to $108.8 million, and management says this funds operations into 2027.
Net loss was $42.1 million, or $0.24 per share, for the quarter ended June 30, 2026, versus $52.6 million, or $0.41 per share, a year earlier.
R&D expenses fell to $33.4 million from $41.4 million, and G&A expenses fell to $11.0 million from $13.1 million.
Collaboration revenue from a related party was $1.15 million, compared with $1.12 million in the prior-year quarter.
Cash and related balances were $108.8 million at June 30, 2026, down from $191.4 million at December 31, 2025.
An arbitration tribunal issued a final award on July 6, 2026, declaring that Prime Medicine's PM647 candidate for Alpha-1 Antitrypsin Deficiency is within the agreement's Field and that the company did not breach its 2019 agreement with Beam Therapeutics. The tribunal denied Beam's requests for damages and injunctive relief and denied the remaining claims by both parties. The ruling removes a breach claim tied to a key development candidate, though the filing gives no financial figures.
Final Award received July 6, 2026 from the arbitration tribunal in proceedings with Beam Therapeutics
Tribunal declared PM647, targeting Alpha-1 Antitrypsin Deficiency, is within the agreement's Field
Tribunal denied Beam's requests for damages and injunctive relief and denied remaining claims by both parties
Prime Medicine reported a first-quarter 2026 net loss of $49.1 million, down from $51.9 million a year earlier, and loss per share of $0.28 versus $0.40. Collaboration revenue fell to $856,000 from $1.454 million, and G&A expenses rose on arbitration-related legal costs. Cash and investments were $149.2 million at March 31, 2026, which the company says funds operations into 2027.
Net loss $49.1 million vs. $51.9 million in Q1 2025; loss per share $0.28 vs. $0.40
Collaboration revenue $856,000 vs. $1.454 million in Q1 2025
R&D expenses $34.1 million vs. $40.6 million; G&A expenses $17.4 million vs. $13.3 million, driven by arbitration-related legal expenses
Cash, cash equivalents, investments and restricted cash $149.2 million at March 31, 2026, vs. $191.4 million at December 31, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Prime Medicine, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →